The bull case for Vir starts to unravel
Hopes for the highly valued biotech’s Covid-19 antibody dim before a more important look at the project’s potential.
Early Covid-19 “win” boosts Veru
Veru’s victory with VERU-111 in Covid-19 is not as clear-cut as is being claimed.
Novavax and J&J join the Covid-19 vaccine push
Relief as two further pandemic vaccines succeed, but the data confirm variants to be a problem.
Vir becomes a biotech bubble poster child
The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.
The pandemic releases its grip on clinical trials
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
